By TIME Video
The Food and Drug Administration approved on Wednesday a new pain pill that was created to discourage abuse, the Associated Press reports.
The new pill, Targiniq ER, combines oxycodone, a potentially addictive opioid used in many pain medications, with naloxone, often used to trim the effects of opioids. The naloxone isn’t activated if the pill is swallowed as normal. If a would-be drug abuser crushes the pill to snort or inject it, however, the naloxone activates. That can potentially make Targiniq ER less attractive to abusers.
“Targiniq ER has properties that are expected to deter, but not totally prevent, abuse of the drug by snorting and injection,” FDA said in a statement.
More Must-Reads from TIME
- Why Trump’s Message Worked on Latino Men
- What Trump’s Win Could Mean for Housing
- The 100 Must-Read Books of 2024
- Sleep Doctors Share the 1 Tip That’s Changed Their Lives
- Column: Let’s Bring Back Romance
- What It’s Like to Have Long COVID As a Kid
- FX’s Say Nothing Is the Must-Watch Political Thriller of 2024
- Merle Bombardieri Is Helping People Make the Baby Decision
Contact us at letters@time.com